Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Cara Therapeutics (NASDAQ: CARA) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE